REVIEW

Recent advances in the understanding and management of polycystic ovary syndrome [version 1; peer review: 3 approved]

Ana L. Rocha¹, Flávia R. Oliveira¹, Rosana C. Azevedo², Virginia A. Silva¹,
Thais M. Peres¹, Ana L. Candido², Karina B. Gomes¹ , Fernando M. Reis¹

¹Department of Obstetrics and Gynecology, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil

²Department of Internal Medicine, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil

³Department of Clinical and Toxicological Analysis, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil

V1 First published: 26 Apr 2019, 8(F1000 Faculty Rev):565
<https://doi.org/10.12688/f1000research.15318.1>

Latest published: 26 Apr 2019, 8(F1000 Faculty Rev):565
<https://doi.org/10.12688/f1000research.15318.1>

Abstract

Polycystic ovary syndrome (PCOS) is a multifaceted condition characterized by chronic anovulation and excess ovarian activity, in contrast to other causes of anovulation that involve ovarian dormancy or primary insufficiency. Recent studies indicated that PCOS is associated with low-grade chronic inflammation and that women with PCOS are at increased risk of non-alcoholic fatty liver disease. The inflammatory and metabolic derangements associated with PCOS are explained in part by the coexistence of insulin resistance and obesity but are further fueled by the androgen excess. New insights into the regulation of hormones and cytokines in muscle and fat tissue support the concept that PCOS is a systemic syndrome. The therapeutic plan should be tailored to the patient phenotype, complaints, and reproductive desire. Of note, the aromatase inhibitor letrozole seems to be more effective than the reference drug clomiphene citrate to treat infertility due to PCOS. Integral management by a multidisciplinary team may help the patients to adhere to lifestyle interventions and thereby reduce body adiposity and recover their metabolic and reproductive health.

Keywords

polycystic ovary syndrome, PCOS, insulin resistance, infertility, menstrual irregularity

Open Peer Review

Approval Status

	1	2	3
version 1 26 Apr 2019

Faculty Reviews are review articles written by the prestigious Members of **Faculty Opinions**. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

1. **Joop SE Laven**, Erasmus University Medical Center (Erasmus MC), Rotterdam, The Netherlands
2. **Mariano Bizzarri**, University La Sapienza, Rome, Italy
3. **Harpal Randeva**, University of Warwick, Coventry, UK

Any comments on the article can be found at the end of the article.

Corresponding author: Fernando M. Reis (reis.ufmg@gmail.com)

Author roles: **Rocha AL:** Conceptualization, Data Curation, Writing – Original Draft Preparation; **Oliveira FR:** Data Curation, Writing – Original Draft Preparation; **Azevedo RC:** Conceptualization, Data Curation, Writing – Review & Editing; **Silva VA:** Data Curation, Writing – Original Draft Preparation; **Peres TM:** Data Curation, Writing – Original Draft Preparation; **Candido AL:** Project Administration, Supervision, Writing – Review & Editing; **Gomes KB:** Conceptualization, Supervision, Writing – Review & Editing; **Reis FM:** Conceptualization, Data Curation, Methodology, Supervision, Writing – Review & Editing

Competing interests: No competing interests were disclosed.

Grant information: This research was supported by Conselho Nacional de Desenvolvimento Científico e Tecnológico (National Council for Scientific and Technological Development).

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright: © 2019 Rocha AL *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Rocha AL, Oliveira FR, Azevedo RC *et al.* **Recent advances in the understanding and management of polycystic ovary syndrome [version 1; peer review: 3 approved]** F1000Research 2019, 8(F1000 Faculty Rev):565 <https://doi.org/10.12688/f1000research.15318.1>

First published: 26 Apr 2019, 8(F1000 Faculty Rev):565 <https://doi.org/10.12688/f1000research.15318.1>

Introduction

Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in women, presenting with several possible combinations of signs and symptoms and a range of phenotypes, which may include reproductive, endocrine, and metabolic alterations. PCOS is characterized by hypothalamic–pituitary–ovary axis dysfunction and anovulation but, unlike other causes of ovulatory failure that feature insufficient ovarian follicle growth or suppressed gonadotropin secretion (or both), PCOS typically includes androgen excess and subtle alterations (not detected by routine tests) in serum levels of gonadotropins and estrogens. PCOS has the potential for serious consequences, including increased risk for the development of endometrial hyperplasia and neoplasia¹. Furthermore, extra-reproductive manifestations of PCOS include insulin resistance (IR), metabolic syndrome (MS), and low-grade chronic inflammation^{2–6}.

In recent years, many advances have been made in the understanding of pathophysiological mechanisms (Figure 1) and thereby in the diagnosis and management of PCOS. We will discuss a limited number of such advancements according to our view of which ones have been more impactful on the health care of women with this syndrome.

Advances and challenges in PCOS understanding

The Rotterdam Consensus, held jointly by the European and the North American associations of reproductive medicine in 2003, defined the diagnostic criteria of PCOS which remain the most used worldwide for both individual diagnosis and research⁷. It defined PCOS as the presence of any two of three features: hyperandrogenism (clinical or biochemical), ovulatory dysfunction (often manifested by menstrual irregularities), and polycystic ovarian morphology (PCOM) by ultrasound. The syndrome is a diagnosis of exclusion that should be established only after evaluation of other causes of anovulation or androgen excess (or both): hypogonadism, hypo- or hyperthyroidism, hyperprolactinemia, 21-hydroxylase deficiency, Cushing's syndrome, and androgen-producing tumors⁷. Despite some controversy about the appropriateness of the Rotterdam criteria to guide PCOS treatments, their utility to predict reproductive outcomes is well established⁸. A recent guideline from the International PCOS Network recommended use of the Rotterdam criteria in adults and the requirement of both oligo-anovulation and hyperandrogenism for PCOS diagnosis in adolescents⁹.

There are several combinations of signs and symptoms that may be accounted for in the diagnosis of PCOS, resulting in

Figure 1. Schematic representation of some pathophysiological mechanisms of polycystic ovary syndrome. The main clinical manifestations are shown in rectangular boxes. Androgens are responsible for dermatological symptoms, while sustained estrogen production by the ovaries and subcutaneous fat without progesterone opposition produces menstrual irregularity and increases the risk of endometrial hyperplasia. Adipokines and myokines may also be involved in the metabolic alterations associated with the syndrome. Insulin resistance and the compensatory hyperinsulinemia are central mechanisms that perpetuate anovulation and lead to metabolic complications. AMH, anti-Müllerian hormone; FSH, follicle-stimulating hormone; IGF-I, insulin-like growth factor I; LH, luteinizing hormone; NAFLD, non-alcoholic fatty liver disease; SHBG, sex hormone-binding globulin.

different phenotypes for the same syndrome. To better understand the pathogenesis of the syndrome, it is important to compare the genetic profiles of women whose diagnosis was based on the different phenotypes. A recent genome-wide meta-analysis from over 10,000 PCOS cases identified 14 independent loci associated with the risk for PCOS, including three novel loci¹⁰. This large-scale study found no difference between the various clinical phenotypes for the association with most of the PCOS-susceptibility loci, suggesting that common genetic traits may underlie the different phenotypes.

Hyperandrogenism is an important clinical characteristic of the syndrome since it is associated with worse prognosis and higher risk of metabolic and cardiovascular disease¹¹. However, recent genetic findings suggest that it may not be the only driver of PCOS manifestations^{10,12}. As diagnosed by the Rotterdam criteria, hyperandrogenism is present in about 60 to 80% of cases. Biochemical hyperandrogenism remains a diagnostic challenge because the assay methods are poorly standardized, there are no universal cutoffs for diagnosis, and some assays for free testosterone quantification are unreliable^{13,14}. Thus, until a sensitive, reproducible, and widely validated testosterone assay becomes available and affordable for clinical practice, the assessment of biochemical hyperandrogenism to confirm or discard PCOS should rely on total serum testosterone, sex hormone-binding globulin (SHBG), and free androgen index using local cutoffs^{13,15}.

Anti-Müllerian hormone (AMH) is a glycoprotein secreted by the granulosa cells of pre-antral and small antral follicles. AMH plays an essential role in sexual differentiation and gonadal function, besides central effects on the hypothalamic–pituitary–gonadal axis. A straightforward experimental study demonstrated that AMH receptor is expressed in gonadotropin-releasing hormone (GnRH) neurons and that intracerebroventricular administration of AMH increases GnRH-dependent luteinizing hormone (LH) pulsatile release¹⁶. There is accumulating evidence that GnRH pulsatility is perturbed in women with PCOS, leading to increased LH pulsatility, which plays an important role in PCOS pathophysiology¹⁷. Serum AMH levels are typically increased in PCOS¹⁸ and therefore AMH-dependent regulation of GnRH release could be involved in the pathophysiology of fertility in women with PCOS¹⁶.

Metabolic profile

IR is so common in PCOS that it can be considered an integral part of the syndrome. IR and glucose metabolism deregulation are currently supposed to play a pathogenic role in the disease. IR leads to compensatory hyperinsulinemia, which increases ovarian androgen synthesis both by direct ovarian actions and by stimulating LH secretion³. IR also induces dyslipidemia, and women with PCOS have an increased risk of type 2 diabetes mellitus and cardiovascular disease⁵.

Another potential metabolic complication of PCOS is non-alcoholic fatty liver disease (NAFLD), defined as hepatic steatosis not explained by alcohol or other specific etiologic agents. NAFLD is mechanistically and epidemiologically linked to

obesity, IR, and MS¹⁹. PCOS is associated with increased risk of NAFLD regardless of the presence of obesity, suggesting that the relationship between PCOS and NAFLD is also explained by other features of PCOS, such as IR and androgen excess. In fact, a systematic review and meta-analysis showed a higher prevalence of NAFLD among women with hyperandrogenic PCOS compared with other phenotypes of the syndrome, while serum androgen levels were higher in PCOS women with NAFLD compared with PCOS women without NAFLD²⁰.

Adipokines and inflammation mediators released by the adipose tissue also contribute to the metabolic alterations found in PCOS⁶. In addition, a number of growth factors, cytokines, and reactive oxygen species produced by the ovaries, liver, and other tissues create a state of chronic inflammation that concurs to maintain the metabolic imbalance of the syndrome^{4,6}.

During the past decade, skeletal muscle has also been identified as a secretory organ that releases cytokines and other peptides, called myokines. Irisin has been identified as an exercise-induced myokine and has been proposed to mediate the beneficial effects of exercise on metabolism²¹. Irisin can induce a change in characteristics of white adipocytes that acquire a “brown” phenotype. This change includes the activation of uncoupling protein 1 (UCP-1), leading to increased respiration and energy expenditure^{21,22}. Irisin is also produced at lower amounts outside the skeletal muscle²³. Brain-derived irisin mediates anxiolytic effects of aerobic exercise²⁴ and protects the brain from synaptic and memory loss in an animal model of Alzheimer’s disease²⁵. Furthermore, *in vivo* irisin infusion improves bone mass and architecture in young male mice²³.

The expression of irisin is positively associated with body mass index (BMI) and muscle mass, and irisin metabolism is abnormal in patients with type 2 diabetes or gestational diabetes²⁶. Zhang *et al.* observed that serum irisin levels were associated with hyperandrogenism but not with oligovulation or PCOM in women with PCOS²⁷. A recent meta-analysis showed that, after adjustment for BMI, patients with PCOS seem to have normal irisin levels; however, irisin response to hyperinsulinemia might be impaired in patients with PCOS²⁸.

It is uncertain whether PCOS is somehow associated with low serum levels of vitamin D. A systematic review found 12 studies with very heterogeneous results and their meta-analysis suggested lower serum 25-(OH)D in PCOS versus controls but no differences in serum 1,25(OH)₂D between the two groups²⁹. More importantly, if a woman with PCOS has vitamin D deficiency, she will be at increased risk of metabolic comorbidities. Vitamin D supplementation may reduce chronic inflammation markers in women with PCOS and vitamin D deficiency^{30,31} but there is no evidence that such therapy improves the metabolic status of patients²⁹.

Polycystic ovarian morphology and the diagnosis of PCOS

PCOM is one of three criteria for diagnosis of PCOS. PCOM is defined as follicle number per ovary of at least 12 or ovarian volume of at least 10 mL or both⁷. However, the latest generation

of ultrasound devices (maximal probe frequencies that exceed 8 MHz) is more sensitive and yields a larger follicle count in the general population; therefore, the current use of the old cutoff can overestimate the prevalence of PCOM³². A group of experts recently proposed the use of higher in-house thresholds (that is, 19 to 25 follicles per ovary) to define PCOM with the new ultrasound machines³³.

Serum AMH levels correlate with follicle number in women with PCOS. Some studies found a good concordance between serum AMH levels and ultrasound results for the diagnosis of PCOM. These studies suggest that serum AMH could be a proxy for ovarian follicle count and an alternative marker of PCOM to be used interchangeably with ultrasound depending on serum AMH and ovarian follicle count availability³⁴. Recent studies show that high levels of AMH (>35 pmol/L) have a good correlation with the diagnosis of PCOM at ultrasound³⁴. However, serum AMH levels should not yet be used as a marker or as a single test for the diagnosis and detection of PCOS^{9,33}.

PCOS at different stages of life

The progression of PCOS during different life stages is poorly known because of the paucity of cohort studies with long-term follow-up. A study compared clinical and biochemical parameters of PCOS women and healthy controls who visited a medical center at a mean age of 29 years and returned 6 years later on average. In this longitudinal sample, aging was associated with an increase in the number of regular menstrual cycles, a decrease in serum androgen levels, and a decrease in IR¹⁸. The reasons for this attenuation of PCOS features over time are not clear. Other studies have focused on PCOS manifestations in specific age groups, as detailed below.

PCOS in childhood. The interaction between a genetic predisposition and some prenatal and postnatal environmental factors seems to take part in the pathophysiology of PCOS. Intrauterine growth retardation or small for gestational age (or both) and high levels of androgens during the intrauterine period could lead to an increased production of glucocorticoids which may induce epigenetic modifications and increase the risk of PCOS³⁵.

PCOS in adolescence. PCOS is often diagnosed in adolescence. Menstrual irregularity, acne, and hirsutism are the major findings in this age group. However, these features of PCOS overlap with those of normal adolescence. Family history of PCOS, overweight or low birth weight, exposure to androgens during gestation, precocious puberty, obesity, and IR are risk factors that are related to the development of the syndrome. The diagnosis of PCOS during adolescence is based on stricter criteria than in adult women. It requires unequivocal hyperandrogenism (for example, moderate to severe hirsutism or persistent elevation of serum testosterone levels or both) and ovulatory dysfunction that persists for more than 2 years after menarche³⁶.

Recent studies showed that adolescents with PCOS have increased risk of MS and should be advised to adopt a healthy lifestyle

at once³⁷. When a diagnosis of PCOS has been established, the possibility of IR manifestations and quality of life issues should be considered. Obesity, overweight, and hyperinsulinemia may be present in adolescents. In addition, eating disorders (bulimia, anorexia, and binge eating) and inadequate diets with large amounts of hypercaloric and industrialized foods are common in adolescence. Dietary orientation, stimulation to physical activity, and self-care should be part of the integral care for adolescent girls.

PCOS in postmenopausal women. Women with PCOS persist with hyperandrogenism even after menopausal transition and continue to manifest metabolic alterations and MS with increased risk of cardiovascular disease. Therefore, postmenopausal women with a history of PCOS during the reproductive years may still have manifestations of the syndrome^{9,38}.

Advances and challenges in PCOS management

Treatment of PCOS should be proposed not only to alleviate symptoms but also to prevent the occurrence of long-term complications. Combined oral contraceptives and antiandrogens are the standard care to reduce androgen levels and treat symptoms while providing endometrial protection³⁹. However, the therapeutic plan should be tailored depending on the desire (or not) of the patient to become pregnant, need for aesthetic approach, and the presence of concomitant metabolic alterations.

The overall goals of therapy of women with PCOS include the mitigation of hyperandrogenic symptoms, management of metabolic abnormalities and reduction of risk factors for type 2 diabetes and cardiovascular disease, prevention of endometrial hyperplasia, planning and obtaining a safe pregnancy if desired, and improving general well-being and quality of life. These goals are ideally achieved by a multidisciplinary team providing patient-centered care (Figure 2).

Metabolism

The first line of treatment in patients with PCOS should be the improvement in lifestyle. In overweight and obese patients, weight loss due to changes in diet and physical activity decreases serum insulin and androgen levels and reduces the risk of developing glucose intolerance and type 2 diabetes⁵. Pharmacological interventions are indicated in the presence of IR/glucose intolerance or dyslipidemia that persist after lifestyle modifications⁴⁰.

Metformin is the most commonly used drug for the metabolic control of these patients⁴¹. The therapeutic effects of metformin as insulin-sensitizing and hypoglycemic agent have been well confirmed in women with PCOS⁴². However, despite what is commonly believed or what observational uncontrolled studies suggest⁴¹, there is no convincing evidence that metformin reduces BMI in women with PCOS compared with placebo⁴². The addition of metformin may have minimal benefit on the BMI of women who receive antiandrogen and combined oral contraceptive³⁹. Metformin does not seem to decrease body adiposity as it has little if any effect on reducing waist circumference and serum triglyceride levels in women with PCOS⁴².

Figure 2. Patient-centered care by a multidisciplinary team may help reach the main goals of polycystic ovary syndrome management. These goals are symptom relief, safe fertility planning, general well-being, and prevention of long-term complications.

Current studies are exploring the hypothesis that genomic variants define the responsiveness to metformin therapy among women with PCOS⁴³. Since metformin often has gastrointestinal side effects, new pharmaceutical preparations especially designed for vaginal delivery are under development and so far have been effective in a preclinical model of PCOS⁴⁴.

Liraglutide is a glucagon-like peptide receptor 1 agonist approved for treating type 2 diabetes and obesity. In obese women with PCOS, liraglutide was effective to induce significant weight loss and reduce waist circumference⁴⁵. Orlistat is a lipase inhibitor labeled for treatment of obesity. In overweight or obese women with PCOS, orlistat is effective to induce weight loss and improve clinical and biochemical markers of hyperandrogenism and IR⁴⁶.

Myo- and D-chiro-inositol are insulin-sensitizing agents that act as second messengers in insulin signaling. These compounds have been evaluated as possible alternatives to metformin in PCOS women with IR. Inositol isoforms mediate insulin activity in many target organs, including the ovary, as detailed in a recent review⁴⁷. In a mouse model of PCOM induced by constant light exposure, the theca/granulosa cell layer thickness ratio and the time to pregnancy were reduced by treatment with myo-inositol and D-chiro-inositol in a 40:1 molar ratio⁴⁸.

Earlier clinical studies without a placebo or metformin group showed a decrease in serum testosterone along with an increase in SHBG levels after 6 months of treatment with myo-inositol alone or associated with D-chiro-inositol⁴⁹ and no difference between D-chiro-inositol alone or combined with myo-inositol on the number of mature oocytes retrieved for *in vitro* fertilization (IVF)⁵⁰. A recent meta-analysis concluded that myo-inositol

supplementation for IVF did not improve oocyte or embryo quality⁵¹.

Given the current body of evidence, we believe that inositol therapy may become an alternative for metabolic improvement of PCOS women who do not tolerate metformin, but robust data with a face-to-face comparison between inositols and metformin are still missing. Three small, single-center randomized controlled studies published in 2017 addressed this question and found better results with either myo-inositol⁵² or metformin⁵³ or similar benefits with the two drugs⁵⁴. According to the International PCOS Network, inositol (in any form) should be considered an experimental therapy in PCOS⁹.

Quality of life

PCOS manifests in women at reproductive age when issues such as finding a partner, initiating sex life, and forming a family are often very relevant. Factors that negatively affect physical appearance or femininity or compromise fertility are sources of great anxiety and can lead to imbalances in the psychosexual sphere⁵⁵. The psychological impact of PCOS may even surpass that of chronic diseases such as asthma, diabetes, arthritis, and coronary heart disease⁵⁶.

Depression and anxiety are highly prevalent in women with PCOS. Dokras *et al.* found a fourfold increase in the prevalence of depressive symptoms in patients with the syndrome when compared with controls, even after adjustment for BMI⁵⁷. Daily fatigue and sleep disorders, changes in appetite, and loss of interest in everyday activities were the most common symptoms⁵⁸. Thus, the evaluation of quality of life in women with PCOS is essential for better care and clinical management of these patients (Figure 3).

Figure 3. Objectives of assessing the quality of life in women with polycystic ovary syndrome.

Infertility

In overweight or obese patients with PCOS who wish to conceive, lifestyle modifications aimed at weight loss should be the milestone of preconception counseling. Loss of 5 to 7% of body weight may be effective to promote menstrual cycle regularization and spontaneous ovulation⁴⁰. If the woman is unable to lose weight or does not restore ovulatory cycles, treatment should be individualized while taking into account the duration of infertility, the woman's age, the risks of pregnancy at this time, and the factors that may be related to her difficulty to lose weight. Preconception care includes folic acid supplementation at a dose of 0.4 mg/day and cessation of smoking and alcohol consumption.

The second line of treatment (after lifestyle interventions) is ovulation induction. This step must be preceded by careful evaluation of other causes of infertility, such as male factor or tubal obstruction, which demand IVF and may coexist with PCOS.

Clomiphene citrate (CC) is the reference therapy for ovulation induction in anovulatory women with PCOS. In the absence of ovulation for three cycles of CC at the highest dose (150 mg/day), the woman can be considered non-responsive and another drug should be introduced as an adjuvant or substitute for CC.

Compared with placebo, metformin reduces serum testosterone levels and increases the frequency of spontaneous ovulation and regular menstrual cycles in patients with PCOS⁴². However, because it achieves lower live birth rates compared with CC, metformin is no longer recommended to induce ovulation^{42,59}.

Furthermore, there is no conclusive evidence about whether the association of metformin with CC differs from CC alone in live birth rates. This makes sense, as the addition of metformin to CC increases the ovulation and clinical pregnancy rates but also the miscarriage rate compared with CC alone^{42,60}. In women resistant to CC, limited evidence suggests that adding metformin may increase the pregnancy rate⁵⁹. Maintaining metformin during gestation does not seem to prevent adverse outcomes^{42,59,61,62} and may indeed increase the risk of future overweight in offspring⁶³.

The aromatase inhibitor letrozole at a dose of 2.5 mg/day may be used as an alternative to induce ovulation in patients who have failed to respond to CC. Many studies suggest that letrozole can be used as first-line therapy in ovulation induction but this use remains off-label. The dose may be increased by 2.5 mg/day to a maximum of 7.5 mg/day. The major advantage of letrozole over CC is better ovulation-inducing response, especially in obese patients, which translates into higher pregnancy and live birth rates^{60,64}. Preliminary data also suggest that letrozole is superior to metformin plus CC to induce ovulation as assessed by the clinical pregnancy rate in an open-label randomized clinical trial⁶⁵.

In case of failure of oral ovulation inducers to achieve pregnancy, injectable gonadotropins combined with timed intercourse, intrauterine insemination, or IVF may be used. The addition of metformin to gonadotropins has shown some benefit in low-complexity treatments (timed intercourse or intraruterine insemination) but not in IVF^{62,66}. Preliminary results suggest that liraglutide at low dose can help to improve the outcome of IVF treatment in obese women with PCOS⁶⁷.

Women with PCOS should be advised about the most opportune moment for pregnancy, taking into account the obstetric, metabolic, and cardiovascular risks that may be present^{68,69}. Therefore, safe contraception is part of the integral care⁷⁰ as it allows postponing pregnancy while implementing lifestyle interventions to lose fat mass and improve the metabolic homeostasis in order to obtain not just a pregnancy but a successful full-term pregnancy with both mother and baby in good health.

Summary and conclusions

New insights into the cross-talk between muscle, fat, brain, and ovary tissue support the concept that PCOS is a systemic syndrome. The classic reproductive and dermatological features of PCOS are just the visible part of a more complex mechanism (Figure 1). The inflammatory and metabolic derangements associated with PCOS are explained in part by the coexistence of IR and obesity but are further fueled by the androgen excess. The therapeutic plan should be tailored to the patient phenotype, complaints, and reproductive desire. Medical treatments have not seen any breakthrough in recent years. Of note, the aromatase inhibitor letrozole seems to be more effective than the reference drug CC to treat infertility due to PCOS. Integral

management by a multidisciplinary team may help patients to adhere to lifestyle interventions and thereby reduce body adiposity and recover their metabolic and reproductive health.

Author contributions

ALR performed the bibliographic search and drafted the manuscript. FRO, RCA, VAS, and TMP assisted in the bibliographic search and in the preparation of text and figures. ALC and KBG evaluated the evidence and edited the manuscript for significant content. FMR conceived the review, evaluated the evidence, and corrected the manuscript. All authors were involved in the revision of the draft manuscript and have agreed to the final content.

Grant information

This research was supported by Conselho Nacional de Desenvolvimento Científico e Tecnológico (National Council for Scientific and Technological Development).

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

- Barry JA, Azizia MM, Hardiman PJ: **Risk of endometrial, ovarian and breast cancer in women with polycystic ovary syndrome: a systematic review and meta-analysis.** *Hum Reprod Update.* 2014; **20**(5): 748–58.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Çakıroğlu Y, Vural F, Vural B: **The inflammatory markers in polycystic ovary syndrome: association with obesity and IVF outcomes.** *J Endocrinol Invest.* 2016; **39**(8): 899–907.
[PubMed Abstract](#) | [Publisher Full Text](#)
- de Leo V, Musacchio MC, Cappelli V, et al.: **Genetic, hormonal and metabolic aspects of PCOS: an update.** *Reprod Biol Endocrinol.* 2016; **14**(1): 38.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Durmus U, Duran C, Ecirli S: **Visceral adiposity index levels in overweight and/or obese, and non-obese patients with polycystic ovary syndrome and its relationship with metabolic and inflammatory parameters.** *J Endocrinol Invest.* 2017; **40**(5): 487–97.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
- McCartney CR, Marshall JC: **CLINICAL PRACTICE. Polycystic Ovary Syndrome.** *N Engl J Med.* 2016; **375**(1): 54–64.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Spritzer PM, Lecke SB, Sattler F, et al.: **Adipose tissue dysfunction, adipokines, and low-grade chronic inflammation in polycystic ovary syndrome.** *Reproduction.* 2015; **149**(5): R219–R227.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group: **Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome.** *Fertil Steril.* 2004; **81**(1): 19–25.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Wang R, Mol BW: **The Rotterdam criteria for polycystic ovary syndrome: evidence-based criteria?** *Hum Reprod.* 2017; **32**(2): 261–4.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
- Teede HJ, Misso ML, Costello MF, et al.: **Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome.** *Hum Reprod.* 2018; **33**(9): 1602–18.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
- Day F, Karaderi T, Jones MR, et al.: **Large-scale genome-wide meta-analysis of polycystic ovary syndrome suggests shared genetic architecture for different diagnosis criteria.** *PLoS Genet.* 2018; **14**(12): e1007813.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
- Daan NM, Jaspers L, Koster MP, et al.: **Androgen levels in women with various forms of ovarian dysfunction: associations with cardiometabolic features.** *Hum Reprod.* 2015; **30**(10): 2376–86.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Dumesic DA, Oberfield SE, Stener-Victorin E, et al.: **Scientific Statement on the Diagnostic Criteria, Epidemiology, Pathophysiology, and Molecular Genetics of Polycystic Ovary Syndrome.** *Endocr Rev.* 2015; **36**(5): 487–525.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Legro RS, Arslanian SA, Ehrmann DA, et al.: **Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline.** *J Clin Endocrinol Metab.* 2013; **98**(12): 4565–92.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Wierman ME, Arit W, Basson R, et al.: **Androgen therapy in women: a reappraisal: an Endocrine Society clinical practice guideline.** *J Clin Endocrinol Metab.* 2014; **99**(10): 3489–510.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Mario FM, Graff SK, Spritzer PM: **Habitual physical activity is associated with improved anthropometric and androgenic profile in PCOS: a cross-sectional study.** *J Endocrinol Invest.* 2017; **40**(4): 377–84.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
- Cimino I, Casoni F, Liu X, et al.: **Novel role for anti-Müllerian hormone in the regulation of GnRH neuron excitability and hormone secretion.** *Nat Commun.* 2016; **7**: 10055.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
- Katulski K, Podfigurna A, Czyżyk A, et al.: **Kisspeptin and LH pulsatile temporal coupling in PCOS patients.** *Endocrine.* 2018; **61**(1): 149–57.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Brown ZA, Louwers YV, Fong SL, et al.: **The phenotype of polycystic ovary syndrome ameliorates with aging.** *Fertil Steril.* 2011; **96**(5): 1259–65.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Mishra A, Younossi ZM: **Epidemiology and Natural History of Non-alcoholic Fatty Liver Disease.** *J Clin Exp Hepatol.* 2012; **2**(2): 135–44.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Rocha ALL, Faria LC, Guimarães TCM, et al.: **Non-alcoholic fatty liver disease in women with polycystic ovary syndrome: systematic review and meta-analysis.** *J Endocrinol Invest.* 2017; **40**(12): 1279–88.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Boström P, Wu J, Jedrychowski MP, et al.: **A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis.** *Nature.* 2012; **481**(7382): 463–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)

22. **F** Polyzos SA, Anastasilakis AD, Efstathiadou ZA, *et al.*: **Irisin in metabolic diseases.** *Endocrine*. 2018; **59**(2): 260–74.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
23. **F** Colaianni G, Cuscito C, Mongelli T, *et al.*: **The myokine irisin increases cortical bone mass.** *Proc Natl Acad Sci U S A*. 2015; **112**(39): 12157–62.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
24. **F** Uysal N, Yuksel O, Kizildag S, *et al.*: **Regular aerobic exercise correlates with reduced anxiety and increased levels of irisin in brain and white adipose tissue.** *Neurosci Lett*. 2018; **676**: 92–7.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
25. **F** Lourenco MV, Frozza RL, de Freitas GB, *et al.*: **Exercise-linked FNDC5/irisin rescues synaptic plasticity and memory defects in Alzheimer's models.** *Nat Med*. 2019; **25**(1): 165–75.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
26. Moreno-Navarrete JM, Ortega F, Serrano M, *et al.*: **Irisin is expressed and produced by human muscle and adipose tissue in association with obesity and insulin resistance.** *J Clin Endocrinol Metab*. 2013; **98**(4): E769–78.
[PubMed Abstract](#) | [Publisher Full Text](#)
27. Zhang L, Fang X, Li L, *et al.*: **The association between circulating irisin levels and different phenotypes of polycystic ovary syndrome.** *J Endocrinol Invest*. 2018; **41**(12): 1401–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
28. **F** Cai X, Qiu S, Li L, *et al.*: **Circulating irisin in patients with polycystic ovary syndrome: a meta-analysis.** *Reprod Biomed Online*. 2018; **36**(2): 172–80.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
29. He C, Lin Z, Robb SW, *et al.*: **Serum Vitamin D Levels and Polycystic Ovary syndrome: A Systematic Review and Meta-Analysis.** *Nutrients*. 2015; **7**(6): 4555–77.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
30. Foroozanfar F, Jamilian M, Bahmani F, *et al.*: **Calcium plus vitamin D supplementation influences biomarkers of inflammation and oxidative stress in overweight and vitamin D-deficient women with polycystic ovary syndrome: A randomized double-blind placebo-controlled clinical trial.** *Clin Endocrinol (Oxf)*. 2015; **83**(6): 888–94.
[PubMed Abstract](#) | [Publisher Full Text](#)
31. Irani M, Seifer DB, Grazi RV, *et al.*: **Vitamin D Supplementation Decreases TGF- β 1 Bioavailability in PCOS: A Randomized Placebo-Controlled Trial.** *J Clin Endocrinol Metab*. 2015; **100**(11): 4307–14.
[PubMed Abstract](#) | [Publisher Full Text](#)
32. Martins WP, Kollmann M, Raine-Fenning N: **Counting ovarian follicles: updated threshold for diagnosis of hyperandrogenic anovulation.** *Ultrasound Obstet Gynecol*. 2014; **44**(2): 131–4.
[PubMed Abstract](#) | [Publisher Full Text](#)
33. Dewailly D, Lujan ME, Carmina E, *et al.*: **Definition and significance of polycystic ovarian morphology: a task force report from the Androgen Excess and Polycystic Ovary Syndrome Society.** *Hum Reprod Update*. 2014; **20**(3): 334–52.
[PubMed Abstract](#) | [Publisher Full Text](#)
34. **F** Fraissinet A, Robin G, Pigny P, *et al.*: **Use of the serum anti-Müllerian hormone assay as a surrogate for polycystic ovarian morphology: impact on diagnosis and phenotypic classification of polycystic ovary syndrome.** *Hum Reprod*. 2017; **32**(8): 1716–22.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
35. **F** Bellver J, Rodríguez-Tabernero L, Robles A, *et al.*: **Polycystic ovary syndrome throughout a woman's life.** *J Assist Reprod Genet*. 2018; **35**(1): 25–39.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
36. Witchel SF, Oberfield S, Rosenfield RL, *et al.*: **The Diagnosis of Polycystic Ovary Syndrome during Adolescence.** *Horm Res Paediatr*. 2015; **83**: 376–389.
[PubMed Abstract](#) | [Publisher Full Text](#)
37. Fitzgerald S, DiVasta A, Gooding H: **An update on PCOS in adolescents.** *Curr Opin Pediatr*. 2018; **30**(4): 459–465.
[PubMed Abstract](#)
38. Shah D, Bansal S: **Polycystic ovaries - beyond menopause.** *Climacteric*. 2014; **17**(2): 109–15.
[PubMed Abstract](#) | [Publisher Full Text](#)
39. **F** Luque-Ramírez M, Nattero-Chávez L, Ortiz Flores AE, *et al.*: **Combined oral contraceptives and/or antiandrogens versus insulin sensitizers for polycystic ovary syndrome: a systematic review and meta-analysis.** *Hum Reprod Update*. 2018; **24**: 225–41.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
40. Balen AH, Morley LC, Misso M, *et al.*: **The management of anovulatory infertility in women with polycystic ovary syndrome: an analysis of the evidence to support the development of global WHO guidance.** *Hum Reprod Update*. 2016; **22**(6): 687–708.
[PubMed Abstract](#) | [Publisher Full Text](#)
41. Yang PK, Hsu CY, Chen MJ, *et al.*: **The Efficacy of 24-Month Metformin for Improving Menses, Hormones, and Metabolic Profiles in Polycystic Ovary Syndrome.** *J Clin Endocrinol Metab*. 2018; **103**(3): 890–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
42. **F** Morley LC, Tang T, Yasmin E, *et al.*: **Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility.** *Cochrane Database Syst Rev*. 2017; **11**: CD003053.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
43. Pedersen AJT, Stage TB, Glintborg D, *et al.*: **The Pharmacogenetics of Metformin in Women with Polycystic Ovary Syndrome: A Randomized Trial.** *Basic Clin Pharmacol Toxicol*. 2018; **122**(2): 239–44.
[PubMed Abstract](#) | [Publisher Full Text](#)
44. Saini N, Sodhi RK, Bajaj L, *et al.*: **Intravaginal administration of metformin hydrochloride loaded cationic niosomes amalgamated with thermosensitive gel for the treatment of polycystic ovary syndrome: In vitro and in vivo studies.** *Colloids Surf B Biointerfaces*. 2016; **144**: 161–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
45. Jensterle M, Kravos NA, Pfeifer M, *et al.*: **A 12-week treatment with the long-acting glucagon-like peptide 1 receptor agonist liraglutide leads to significant weight loss in a subset of obese women with newly diagnosed polycystic ovary syndrome.** *HHormones (Athens)*. 2015; **14**(1): 81–90.
[PubMed Abstract](#) | [Publisher Full Text](#)
46. Graff SK, Mario FM, Ziegelmann P, *et al.*: **Effects of orlistat vs. metformin on weight loss-related clinical variables in women with PCOS: systematic review and meta-analysis.** *Int J Clin Pract*. 2016; **70**(6): 450–61.
[PubMed Abstract](#) | [Publisher Full Text](#)
47. Monasta G, Unfer V, Harraath AH, *et al.*: **Combining treatment with myo-inositol and D-chiro-inositol (40:1) is effective in restoring ovary function and metabolic balance in PCOS patients.** *Gynecol Endocrinol*. 2017; **33**(1): 1–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
48. Bevilacqua A, Dragotto J, Giuliani A, *et al.*: **Myo-inositol and D-chiro-inositol (40:1) reverse histological and functional features of polycystic ovary syndrome in a mouse model.** *J Cell Physiol*. 2019; **234**(6): 9387–9398.
[PubMed Abstract](#) | [Publisher Full Text](#)
49. Nordio M, Proietti E: **The combined therapy with myo-inositol and D-chiro-inositol reduces the risk of metabolic disease in PCOS overweight patients compared to myo-inositol supplementation alone.** *Eur Rev Med Pharmacol Sci*. 2012; **16**(5): 575–81.
[PubMed Abstract](#)
50. Colazingari S, Treglia M, Najjar R, *et al.*: **The combined therapy myo-inositol plus D-chiro-inositol, rather than D-chiro-inositol, is able to improve IVF outcomes: results from a randomized controlled trial.** *Arch Gynecol Obstet*. 2013; **288**(6): 1405–11.
[PubMed Abstract](#) | [Publisher Full Text](#)
51. **F** Mendoza N, Pérez L, Simoncini T, *et al.*: **Inositol supplementation in women with polycystic ovary syndrome undergoing intracytoplasmic sperm injection: a systematic review and meta-analysis of randomized controlled trials.** *Reprod Biomed Online*. 2017; **35**(5): 529–35.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
52. Jamilian M, Farhat P, Foroozanfar F, *et al.*: **Comparison of myo-inositol and metformin on clinical, metabolic and genetic parameters in polycystic ovary syndrome: A randomized controlled clinical trial.** *Clin Endocrinol (Oxf)*. 2017; **87**(2): 194–200.
[PubMed Abstract](#) | [Publisher Full Text](#)
53. Tagliaferri V, Romualdi D, Immediata V, *et al.*: **Metformin vs myoinositol: which is better in obese polycystic ovary syndrome patients? A randomized controlled crossover study.** *Clin Endocrinol (Oxf)*. 2017; **86**(5): 725–30.
[PubMed Abstract](#) | [Publisher Full Text](#)
54. Fruzzetti F, Perini D, Russo M, *et al.*: **Comparison of two insulin sensitizers, metformin and myo-inositol, in women with polycystic ovary syndrome (PCOS).** *Gynecol Endocrinol*. 2016; **33**(1): 39–42.
[PubMed Abstract](#) | [Publisher Full Text](#)
55. Eggers S, Kirchengast S: **The polycystic ovary syndrome—a medical condition but also an important psychosocial problem.** *Coll Antropol*. 2001; **25**(2): 673–85.
[PubMed Abstract](#)
56. Coffey S, Bano G, Mason HD: **Health-related quality of life in women with polycystic ovary syndrome: a comparison with the general population using the Polycystic Ovary Syndrome Questionnaire (PCOSQ) and the Short Form-36 (SF-36).** *Gynecol Endocrinol*. 2006; **22**(2): 80–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
57. Dokras A, Clifton S, Futterweit W, *et al.*: **Increased risk for abnormal depression scores in women with polycystic ovary syndrome: a systematic review and meta-analysis.** *Obstet Gynecol*. 2011; **117**(1): 145–52.
[PubMed Abstract](#) | [Publisher Full Text](#)
58. Dokras A: **Mood and anxiety disorders in women with PCOS.** *Steroids*. 2012; **77**(4): 338–41.
[PubMed Abstract](#) | [Publisher Full Text](#)
59. Practice Committee of the American Society for Reproductive Medicine: **Role of metformin for ovulation induction in infertile patients with polycystic ovary syndrome (PCOS): a guideline.** *Fertil Steril*. 2017; **108**(3): 426–41.
[PubMed Abstract](#) | [Publisher Full Text](#)
60. **F** Wang R, Kim BV, van Wely M, *et al.*: **Treatment strategies for women with WHO group II anovulation: systematic review and network meta-analysis.** *BMJ*. 2017; **356**: j138.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
61. Legro RS: **Ovulation induction in polycystic ovary syndrome: Current options.** *Best Pract Res Clin Obstet Gynaecol*. 2016; **37**: 152–9.
[PubMed Abstract](#) | [Publisher Full Text](#)

62. Bordewijk EM, Nahuis M, Costello MF, *et al.*: **Metformin during ovulation induction with gonadotrophins followed by timed intercourse or intrauterine insemination for subfertility associated with polycystic ovary syndrome.** *Cochrane Database Syst Rev.* 2017; 1: CD009090.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
63. Hanem LGE, Stridsklev S, Júlíusson PB, *et al.*: **Metformin Use in PCOS Pregnancies Increases the Risk of Offspring Overweight at 4 Years of Age: Follow-Up of Two RCTs.** *J Clin Endocrinol Metab.* 2018; 103(4): 1612–21.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
64. Franik S, Eltrop SM, Kremer JA, *et al.*: **Aromatase inhibitors (letrozole) for subfertile women with polycystic ovary syndrome.** *Cochrane Database Syst Rev.* 2018; 5: CD010287.
[PubMed Abstract](#) | [Publisher Full Text](#)
65. Rezk M, Shaheen AE, Saif El-Nasr I: **Clomiphene citrate combined with metformin versus letrozole for induction of ovulation in clomiphene-resistant polycystic ovary syndrome: a randomized clinical trial.** *Gynecol Endocrinol.* 2018; 34(4): 298–300.
[PubMed Abstract](#) | [Publisher Full Text](#)
66. Kalem MN, Kalem Z, Gurgan T: **Effect of metformin and oral contraceptives on polycystic ovary syndrome and IVF cycles.** *J Endocrinol Invest.* 2017; 40(7): 745–52.
[PubMed Abstract](#) | [Publisher Full Text](#)
67. Salamun V, Jensterle M, Janez A, *et al.*: **Liraglutide increases IVF pregnancy rates in obese PCOS women with poor response to first-line reproductive treatments: a pilot randomized study.** *Eur J Endocrinol.* 2018; 179(1): 1–11.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
68. Palomba S, de Wilde MA, Falbo A, *et al.*: **Pregnancy complications in women with polycystic ovary syndrome.** *Hum Reprod Update.* 2015; 21(5): 575–92.
[PubMed Abstract](#) | [Publisher Full Text](#)
69. Yu HF, Chen HS, Rao DP, *et al.*: **Association between polycystic ovary syndrome and the risk of pregnancy complications: A PRISMA-compliant systematic review and meta-analysis.** *Medicine (Baltimore).* 2016; 95(51): e4863.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
70. Rocha ALL, Campos RR, Miranda MMS, *et al.*: **Safety of hormonal contraception for obese women.** *Expert Opin Drug Saf.* 2017; 16(12): 1387–93.
[PubMed Abstract](#) | [Publisher Full Text](#)

Open Peer Review

Current Peer Review Status:

Editorial Note on the Review Process

Faculty Reviews are review articles written by the prestigious Members of **Faculty Opinions**. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

The reviewers who approved this article are:

Version 1

1. **Harpal Randeva**

Division of Translational and Experimental Medicine, Warwick Medical School, University of Warwick, Coventry, UK

Competing Interests: No competing interests were disclosed.

2. **Mariano Bizzarri**

Department of Experimental Medicine, Systems Biology Group, University La Sapienza, Rome, Italy

Competing Interests: No competing interests were disclosed.

3. **Joop SE Laven**

Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynaecology, Erasmus University Medical Center (Erasmus MC), Rotterdam, The Netherlands

Competing Interests: No competing interests were disclosed.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research